Zhangqian Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhangqian Chen has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Daiming Fan
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China
2 shared publications Jiuping Wang
Department of Infectious Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, PR China
2 shared publicationsXiaoyu Kang
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shaanxi, PR China
2 shared publications- Yongzhan Nie
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China
2 shared publications Chao Zeng
Department of Cardiology, The 74th Group Army Hospital, Guangzhou, 510318, China
1 shared publication- Chaoxu Liu
Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 201907, China
1 shared publication
Latest Publications
- Open Access
- 17 October 2025
- Published by Elsevier in Pharmacological Research
- Vol. 221, 107996
Discovery of KMT5A repressed miR-99b cluster with potential to restore chemotherapy sensitivity in gastric cancer by regulating mitochondrial complex II and affecting OXPHOS
- 17 October 2025
- Published by Elsevier in Pharmacological Research
- Vol. 221, 107996
Open AccessDiscovery of KMT5A repressed miR-99b cluster with potential to restore chemotherapy sensitivity in gastric cancer by regulating mitochondrial complex II and affecting OXPHOS
- Open Access
- 27 January 2025
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 11 (1) , e70015
Platinum drugs upregulate CXCR4 and PD‐L1 expression via ROS‐dependent pathways, with implications for novel combined treatment in gastric cancer
CXC chemokine receptor 4 (CXCR4) and programmed cell death‐ligand 1 (PD‐L1) are two critical molecules involved in the tumor immune microenvironment. However, the impact of platinum drugs, such as cisplatin, on CXCR4 or PD‐L1 expression and the underlying mechanisms in gastric cancer (GC) remain unknown. Moreover, the correlation between their expression levels in GC remains elusive. Immunohistochemistry, western blot, and RT‐qPCR were performed to determine the expression pattern of CXCR4 and PD‐L1 in GC. Clinical samples, patient‐derived xenografts, and cell‐derived xenografts were utilized to investigate the effects of platinum drugs on the expression levels of CXCR4 and PD‐L1. Postchemotherapy resected GC tumor tissues showed higher CXCR4 and PD‐L1 expression levels than pretreatment biopsies (p < 0.05). Similarly, GC xenografts treated with platinum‐based chemotherapy exhibited increased CXCR4 and PD‐L1 expression levels compared to saline‐treated controls (p < 0.05). A positive correlation was detected between the expression levels of CXCR4 and PD‐L1 in GC tumor tissues. Increased levels of CXCR4 and PD‐L1 expression, in a dose‐ and time‐dependent manner upon cisplatin treatment, were observed in GC cells (p < 0.05). Cisplatin‐induced CXCR4 upregulation relies on ROS/HIF‐1α and ROS/NF‐κB pathways, while cisplatin‐induced PD‐L1 upregulation is cyclic GMP‐AMP synthase/stimulator of IFN genes‐dependent and associated with elevated ROS levels in GC cells. CXCR4 expression was found to be positively correlated with PD‐L1 expression in GC. Platinum drugs upregulated the levels of CXCR4 and PD‐L1 expression in GC. A combined strategy targeting CXCR‐4 and PD‐L1 might have clinical prospects for GC patients.
- 27 January 2025
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 11 (1) , e70015
Open AccessPlatinum drugs upregulate CXCR4 and PD‐L1 expression via ROS‐dependent pathways, with implications for novel combined treatment in gastric cancer
CXC chemokine receptor 4 (CXCR4) and programmed cell death‐ligand 1 (PD‐L1) are two critical molecules involved in the tumor immune microenvironment. However, the impact of platinum drugs, such as cisplatin, on CXCR4 or PD‐L1 expression and the underlying mechanisms in gastric cancer (GC) remain unknown. Moreover, the correlation between their expression levels in GC remains elusive. Immunohistochemistry, western blot, and RT‐qPCR were performed to determine the expression pattern of CXCR4 and PD‐L1 in GC. Clinical samples, patient‐derived xenografts, and cell‐derived xenografts were utilized to investigate the effects of platinum drugs on the expression levels of CXCR4 and PD‐L1. Postchemotherapy resected GC tumor tissues showed higher CXCR4 and PD‐L1 expression levels than pretreatment biopsies (p < 0.05). Similarly, GC xenografts treated with platinum‐based chemotherapy exhibited increased CXCR4 and PD‐L1 expression levels compared to saline‐treated controls (p < 0.05). A positive correlation was detected between the expression levels of CXCR4 and PD‐L1 in GC tumor tissues. Increased levels of CXCR4 and PD‐L1 expression, in a dose‐ and time‐dependent manner upon cisplatin treatment, were observed in GC cells (p < 0.05). Cisplatin‐induced CXCR4 upregulation relies on ROS/HIF‐1α and ROS/NF‐κB pathways, while cisplatin‐induced PD‐L1 upregulation is cyclic GMP‐AMP synthase/stimulator of IFN genes‐dependent and associated with elevated ROS levels in GC cells. CXCR4 expression was found to be positively correlated with PD‐L1 expression in GC. Platinum drugs upregulated the levels of CXCR4 and PD‐L1 expression in GC. A combined strategy targeting CXCR‐4 and PD‐L1 might have clinical prospects for GC patients.
- Open Access
- 27 September 2023
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 11 (9) , e1033
Clinical and virological features of asymptomatic and mild symptomatic patients with SARS‐CoV‐2 Omicron infection at Shanghai Fangcang shelter hospital
Objective: The objective of this study is to evaluate and compare clinical and virological characteristics of asymptomatic and mild symptomatic patients of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron BA.2.2 variant infection and identify risk factors associated with the prolonged viral negative conversion duration.Methods: We conducted a retrospective observational study in a Shanghai (China) Fangcang shelter hospital from April 9 to May 17, 2022. The patient‐related demographic or clinical data were retrospectively recorded. Comparisons of demographic and clinical characteristics between asymptomatic and mild‐symptomatic patients were performed. Cox regression was performed to identify the risk factors of prolonged viral negative conversion duration.Results: A total of 551 patients confirmed with SARS‐CoV‐2 Omicron variant infection were enrolled in the study. Of these, 297 patients (53.9%) were asymptomatic and 254 patients (46.1%) had mild symptoms. When comparing the clinical and virological characteristics between the asymptomatic and mild symptomatic groups, several clinical parameters, including age, gender, time to viral clearance from the first positive swab, chronic comorbidities, and vaccination dose did not show statistically significant differences. In mild symptomatic patients, the median viral negative conversion duration (NCD) was 7 days (interquartile range [IQR]: 5–9), which was comparable to the median of 7 days (IQR: 5–10) in asymptomatic patients (p = .943). Multivariate Cox analysis revealed that patients age ≥ 60 years had a significantly higher hazard ratio (HR) for prolonged viral NCD (HR: 1.313; 95% confidence interval: 1.014–1.701, p = .039).Conclusion: Asymptomatic and symptomatic patients with non‐severe SARS‐CoV‐2 Omicron BA.2.2 variant infection have similar clinical features and virological courses. Old age was an independent risk factor for prolonged SARS‐CoV‐2 conversion time.
- 27 September 2023
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 11 (9) , e1033
Open AccessClinical and virological features of asymptomatic and mild symptomatic patients with SARS‐CoV‐2 Omicron infection at Shanghai Fangcang shelter hospital
Objective: The objective of this study is to evaluate and compare clinical and virological characteristics of asymptomatic and mild symptomatic patients of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron BA.2.2 variant infection and identify risk factors associated with the prolonged viral negative conversion duration.Methods: We conducted a retrospective observational study in a Shanghai (China) Fangcang shelter hospital from April 9 to May 17, 2022. The patient‐related demographic or clinical data were retrospectively recorded. Comparisons of demographic and clinical characteristics between asymptomatic and mild‐symptomatic patients were performed. Cox regression was performed to identify the risk factors of prolonged viral negative conversion duration.Results: A total of 551 patients confirmed with SARS‐CoV‐2 Omicron variant infection were enrolled in the study. Of these, 297 patients (53.9%) were asymptomatic and 254 patients (46.1%) had mild symptoms. When comparing the clinical and virological characteristics between the asymptomatic and mild symptomatic groups, several clinical parameters, including age, gender, time to viral clearance from the first positive swab, chronic comorbidities, and vaccination dose did not show statistically significant differences. In mild symptomatic patients, the median viral negative conversion duration (NCD) was 7 days (interquartile range [IQR]: 5–9), which was comparable to the median of 7 days (IQR: 5–10) in asymptomatic patients (p = .943). Multivariate Cox analysis revealed that patients age ≥ 60 years had a significantly higher hazard ratio (HR) for prolonged viral NCD (HR: 1.313; 95% confidence interval: 1.014–1.701, p = .039).Conclusion: Asymptomatic and symptomatic patients with non‐severe SARS‐CoV‐2 Omicron BA.2.2 variant infection have similar clinical features and virological courses. Old age was an independent risk factor for prolonged SARS‐CoV‐2 conversion time.
- Open Access
- 4 May 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (5) , 1-13
Oncogenic driver genes and tumor microenvironment determine the type of liver cancer
Primary liver cancer (PLC) may be mainly classified as the following four types: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), hepatoblastoma (HB), and combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (cHCC-ICC). The majority of PLC develops in the background of tumor microenvironment, such as inflammatory microenvironments caused by viral hepatitis, alcoholic or nonalcoholic steatohepatitis, carbon tetrachloride (CCl4), 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), and necroptosis-associated hepatic cytokine microenvironment caused by necroptosis of hepatocytes. However, the impact of different types of microenvironments on the phenotypes of PLC generated by distinct oncogenes is still unclear. In addition, the cell origin of different liver cancers have not been clarified, as far as we know. Recent researches show that mature hepatocytes retain phenotypic plasticity to differentiate into cholangiocytes. More importantly, our results initially demonstrated that HCC, ICC, and cHCC-ICC could originate from mature hepatocytes rather than liver progenitor cells (LPCs), hepatic stellate cells (HSCs) and cholangiocytes in AKT-driven, AKT/NICD-driven and AKT/CAT-driven mouse PLC models respectively by using hydrodynamic transfection methodology. Therefore, liver tumors originated from mature hepatocytes embody a wide spectrum of phenotypes from HCC to CC, possibly including cHCC-ICC and HB. However, the underlying mechanism determining the cancer phenotype of liver tumors has yet to be delineated. In this review, we will provide a summary of the possible mechanisms for directing the cancer phenotype of liver tumors (i.e., ICC, HCC, and cHCC-ICC) in terms of oncogenic driver genes and tumor microenvironment. Moreover, this study initially revealed the cell origin of different types of liver cancer.
- 4 May 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (5) , 1-13
Open AccessOncogenic driver genes and tumor microenvironment determine the type of liver cancer
Primary liver cancer (PLC) may be mainly classified as the following four types: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), hepatoblastoma (HB), and combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (cHCC-ICC). The majority of PLC develops in the background of tumor microenvironment, such as inflammatory microenvironments caused by viral hepatitis, alcoholic or nonalcoholic steatohepatitis, carbon tetrachloride (CCl4), 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), and necroptosis-associated hepatic cytokine microenvironment caused by necroptosis of hepatocytes. However, the impact of different types of microenvironments on the phenotypes of PLC generated by distinct oncogenes is still unclear. In addition, the cell origin of different liver cancers have not been clarified, as far as we know. Recent researches show that mature hepatocytes retain phenotypic plasticity to differentiate into cholangiocytes. More importantly, our results initially demonstrated that HCC, ICC, and cHCC-ICC could originate from mature hepatocytes rather than liver progenitor cells (LPCs), hepatic stellate cells (HSCs) and cholangiocytes in AKT-driven, AKT/NICD-driven and AKT/CAT-driven mouse PLC models respectively by using hydrodynamic transfection methodology. Therefore, liver tumors originated from mature hepatocytes embody a wide spectrum of phenotypes from HCC to CC, possibly including cHCC-ICC and HB. However, the underlying mechanism determining the cancer phenotype of liver tumors has yet to be delineated. In this review, we will provide a summary of the possible mechanisms for directing the cancer phenotype of liver tumors (i.e., ICC, HCC, and cHCC-ICC) in terms of oncogenic driver genes and tumor microenvironment. Moreover, this study initially revealed the cell origin of different types of liver cancer.